Apolipoprotein A proteoforms and their associations with indices of cardiometabolic health

In collaboration with:

 

Description: ApoAI (apolipoproteins AI) and apoAII (apolipoprotein AII) are structural and functional proteins of high‐density lipoproteins (HDL) which undergo post‐translational modifications at specific residues, creating distinct proteoforms. While specific post‐translational modifications have been reported to alter apolipoprotein function, the full spectrum of apoAI and apoAII proteoforms and their associations with cardiometabolic phenotype remains unknown. We developed a method to comprehensively characterize apoAI and apoAII proteoforms detectable in serum and their post‐translational modifications and quantify their associations with cardiometabolic health indices.

 

Apolipoprotein proteoform analysis. A, The proteoform profile of a gene product. B, Study design and workflow used to characterize and quantify apoAI and apoAII proteoforms.

 

Project status: Finalized

Publications:

– A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity. 2018. DOI: 10.1021/acs.jproteome.8b00100

– Spectrum of Apolipoprotein AI and Apolipoprotein AII Proteoforms and Their Associations With Indices of Cardiometabolic Health: The CARDIA Study. 2021. DOI: 10.1161/JAHA.120.019890

Congress Presentations:

– ASMS 2019, ASMS 2020